Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C-Reference-Cited by-同舟云学术

Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C

Published:2018-08-13 Issue:12 Volume:90 Page:1834-1840
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Morio Kei¹,Imamura Michio¹²,Kawakami Yoshiiku¹²,Nakamura Yuki¹,Hatooka Masahiro¹,Morio Reona¹,Fujino Hatsue¹²,Nakahara Takashi¹²,Murakami Eisuke¹²,Kawaoka Tomokazu¹²,Tsuge Masataka¹²,Hiramatsu Akira¹²,Aikata Hiroshi¹²,Hayes C. Nelson¹²,Miki Daiki²³,Ochi Hidenori²³,Katamura Yoshio⁴,Arataki Keiko⁵,Moriya Takashi⁶,Ito Hiroyuki⁷,Tsuji Keiji⁸,Kohno Hiroshi⁹,Waki Koji¹⁰,Tamura Toru¹¹,Nakamura Toshio¹²,Chayama Kazuaki¹²³^ORCID,

Affiliation:

1. Department of Gastroenterology and Metabolism, Applied Life Science; Institute of Biomedical & Health Science, Hiroshima University; Hiroshima Japan

2. Research Center for Hepatology and Gastroenterology, Hiroshima University; Hiroshima Japan

3. Laboratory for Digestive Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN); Hiroshima Japan

4. Department of Gastroenterology; Onomichi General Hospital; Onomichi Japan

5. Department of Gastroenterology; Tsuchiya General Hospital; Hiroshima Japan

6. Department of Gastroenterology; Chugoku Rousai Hospital; Kure Japan

7. Department of Internal Medicine; Saiseikai Kure Hospital; Kure Japan

8. Department of Gastroenterology; Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital; Hiroshima Japan

9. Department of Gastroenterology; National Hospital Organization, Kure Medical Center and Chugoku Cancer Center; Kure Japan

10. Department of Gastroenterology; Hiroshima City Asa Hospital; Hiroshima Japan

11. Department of Gastroenterology; Mazda Hospital; Hiroshima Japan

12. Nakamura Clinic; Hiroshima Japan

Funder

Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jmv.25267/fullpdf

Reference27 articles.

1. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus;Kiyosawa;Hepatology,1990

2. Prognosis of chronic hepatitis C: results of a large, prospective cohort study;Niederau;Hepatology,1998

3. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection;Kumada;J Gastroenterol,2018

4. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis;Chayama;J Gastroenterol,2018

5. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C;Tanaka;Nat Genet,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

2. Hepatitis C virus: A critical approach to who really needs treatment;World Journal of Hepatology;2022-01-27

3. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi;Pakistan Journal of Medical Sciences;2021-10-06

4. Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI;European Journal of Gastroenterology & Hepatology;2021-06-03

5. The potential hepatoprotective effect of metformin in hepatitis C virus‐infected adolescent patients with beta thalassemia major: Randomised clinical trial;International Journal of Clinical Practice;2021-03-17